Stock Research for BLUE


Featured Broker: Ally Invest

Get the due diligence for another stock.


BLUE Stock Chart & Research Data

The BLUE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLUE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BLUE Due diligence Resources & Stock Charts

The BLUE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BLUE Detailed Price Forecast - CNN Money CNN View BLUE Detailed Summary - Google Finance
Yahoo View BLUE Detailed Summary - Yahoo! Finance Zacks View BLUE Stock Research & Analysis -

Stock Analysis

TradeIdeas View BLUE Trends & Analysis - Trade-Ideas Barrons View BLUE Major Holders - Barrons
NASDAQ View BLUE Call Transcripts - NASDAQ Seeking View BLUE Breaking News & Analysis - Seeking Alpha
Spotlight View BLUE Annual Report - OTC Report View BLUE OTC Short Report -
TradeKing View BLUE Fundamentals - TradeKing Charts View BLUE SEC Filings - Bar Chart
WSJ View Historical Prices for BLUE - The WSJ Morningstar View Performance/Total Return for BLUE - Morningstar
MarketWatch View the Analyst Estimates for BLUE - MarketWatch CNBC View the Earnings History for BLUE - CNBC
StockMarketWatch View the BLUE Earnings - StockMarketWatch MacroAxis View BLUE Buy or Sell Recommendations - MacroAxis
Bullish View the BLUE Bullish Patterns - American Bulls Short Pains View BLUE Short Pain Metrics -

Social Media Mentions

StockTwits View BLUE Stock Mentions - StockTwits PennyStocks View BLUE Stock Mentions - PennyStockTweets
Twitter View BLUE Stock Mentions - Twitter Invest Hub View BLUE Investment Forum News - Investor Hub
Yahoo View BLUE Stock Mentions - Yahoo! Message Board Seeking Alpha View BLUE Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BLUE - Insider Cow View Insider Transactions for BLUE - Insider Cow
CNBC View BLUE Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BLUE - OTC Markets
Yahoo View Insider Transactions for BLUE - Yahoo! Finance NASDAQ View Institutional Holdings for BLUE - NASDAQ

Stock Charts

FinViz View BLUE Stock Insight & Charts - StockCharts View BLUE Investment Charts -
BarChart View BLUE Stock Overview & Charts - BarChart Trading View View BLUE User Generated Charts - Trading View

Latest Financial News for BLUE

Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
Posted on Friday September 14, 2018

Cellular cancer therapies are a tough sell that could get a lot tougher.

Analyzing Regenxbio’s Valuation Metrics
Posted on Thursday September 13, 2018

Regenxbio (RGNX) generated revenues, chiefly from licensing, of $40.03 million in the second quarter compared to $6.56 million in Q2 2017. For fiscal 2018, Regenxbio is expected to generate revenues of $194.55 million compared to $10.39 million in fiscal 2017. The increase in revenues helped Regenxbio generate a net income of $10.59 million in the second quarter compared to a net loss of $14.47 million in the second quarter of 2017.

Bluebird Bio Stock May Have Upside of at Least 60 Percent
Posted on Wednesday September 12, 2018

Just as Bluebird Bio (NASDAQ:BLUE) started gaining traction in the markets in August, the stock erased all those gains since the start of September. And the month is hardly over. Why did BLUE stock fall 12% last week when the company did not issue any news that would explain what changed, fundamentally?

56% of Analysts Recommend a ‘Buy’ for Editas Medicine
Posted on Monday September 10, 2018

In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.